Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris

Jizhou Li(Czech Academy of Sciences, Institute of Microbiology), Frédéric Lamoth(Czech Academy of Sciences, Institute of Microbiology), Dominique Sanglard(University of Lausanne), Alix T. Coste(Czech Academy of Sciences, Institute of Microbiology), Daniel Bachmann(University of Lausanne)
Antimicrobial Agents and Chemotherapy
March 28, 2022
10.1128/aac.00067-22
Cited by 55

Related Papers

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Antifungal Resistance and New Strategies to Control Fungal Infections
|International Journal of Microbiology|2011|504
Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in <i>Candida albicans</i> Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients
|Antimicrobial Agents and Chemotherapy|2001|471
A Mutation in Tac1p, a Transcription Factor Regulating <i>CDR1</i> and <i>CDR2</i>, Is Coupled With Loss of Heterozygosity at Chromosome 5 to Mediate Antifungal Resistance in <i>Candida albicans</i>
|Genetics|2006|383